drugset
drugset / Trial / NCT02218008

A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - FORWARD-5 Study

NCT02218008 ↗

Phase 3 Completed 407 enrolled Alkermes, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will evaluate the efficacy and safety of ALKS 5461.

Timeline

Start
2014-07
Primary completion
2016-09
Completion
2016-10

Drugs

EvaluationDrugModalityDoseRoute
Subject ALKS 5461 Unknown — Other

Indications

major depressive disorder